Delineating Pro-Angiogenic Myeloid Cells in Cancer Therapy

International Journal of Molecular Sciences

卷:19

BhageluR. Achyut¹  Sadanand Fulzele²  Ravindra Kolhe³  AshisK. Mondal³  BenjaminW. Johnson³  AliS. Arbab⁴ 

[1] Cancer Animal Models Shared Resource, Winship Cancer Center of Emory University, Atlanta, GA 30322, USA;

[2] Department of Orthopedics, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA;

[3] Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA;

[4] Tumor Angiogenesis Laboratory, Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA;

关键词: angiogenic;    myeloid;    chemotherapy;    radiotherapy;    immunotherapy;    antiangiogenic;    MDSC;    tumor;   

DOI  :  10.3390/ijms19092565

来源: DOAJ

【 摘 要 】

Recent evidence suggests that myeloid cells are critical in cancer development and therapy resistance processes. Pharmacological targeting of tumor-associated myeloid cells is an emerging approach among upcoming immune therapies. Surprisingly, myeloid cells are heterogeneous, including a subset of the myeloid cell displaying angiogenic properties in solid tumors. There is an urgent need to delineate angiogenic myeloid cell populations in order to facilitate specific targeting of protumor myeloid cells among heterogeneous pool. This review article is intended to compile all the relevant information in the literature for improved understanding of angiogenic myeloid cells and their role in tumor refractoriness to cancer therapy.

【 授权许可】

Unknown